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Materials and Methods 
Unless otherwise noted, all chemicals and reagents for chemical reactions were obtained from 
commercial suppliers (Sigma-Aldrich, Acros) and used without further purification. Silica gel 
chromatography purifications were carried out using AMD Silica Gel 60, 230-400 mesh. 1H and 13C 
NMR spectra were recorded on either a Varian Mercury 300 spectrometer (300 MHz and 75 MHz, 
respectively) or a Varian Inova 500 MHz (500 MHz and 126 MHz, respectively) and are internally 
referenced to residual solvent peak for chloroform. Data for 1H NMR are reported in the conventional 
form: chemical shift (δ ppm), multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, 
br=broad), coupling constant (Hz), integration. High-resolution mass spectra were obtained with a JEOL 
JMS-600H High Resolution Mass Spectrometer at the California Institute of Technology Mass Spectral 
Facility. Reactions were monitored using thin layer chromatography (Merck 60 silica gel plates) using an 
UV light for visualization and an acidic mixture of anisaldehyde, phosphomolybdic acid, or ceric 
ammonium molybdate, or basic aqueous KMnO4 as developing agents. Gas chromatography (GC) 
analyses were carried out using a Shimadzu GC-17A gas chromatograph with FID detector and J&W HP-
5 column (30 m x 0.32 mm, 0.25 µm film) and 2-phenylethanol as an internal standard.  Gas 
chromatography mass spectrometry (GC-MS) analyses were carried out using a Shimadzu TQ8030 GC-
MS with ion count detector and J&W HP-5 column (30 m x 0.32 mm, 0.25 µM film). Analytical SFC 
was performed with a Mettler SFC supercritical CO2 analytical chromatography system utilizing 
Chiralpak AS column or OD column (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd. 
Semi-preparative HPLC was performed using an Agilent 1200 series, a UV detector, and an Agilent 
XDB-C18 column (9.4 mm x 250 mm, 5 µm).
Plasmids pCWori[BM3] and pET22 were used as cloning vectors. Site-directed mutagenesis was 
accomplished by a modified Quikchange protocol using primers bearing desired mutations (IDT, San 
Diego, CA). Restriction enzymes BamHI, EcoRI, XhoI, Phusion polymerase, and T4 ligase were 
purchased from New England Biolabs (NEB, Ipswich, MA). 
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General Procedures
CO binding assay. CO assay was used to determine the concentration in crude lysate.  Cells were lysed 
by sonication and two cuvettes containing crude lysate with hemoprotein of unknown concentration were 
prepared.  Carbon monoxide was gently bubbled through one solution for 30 seconds and Na2S2O4 (<2 
mg) was added immediately.  Na2S2O4 (2 mg) was added to the other cuvette as well and both were 
sealed with parafilm.  Hemoprotein concentration was determined from ferrous CO binding difference 
spectrum between the two samples using extinction coefficients of ε422-490 = 180 mM-1 cm-1 for histidine-
ligated BM3.1 
Small scale whole cell reactions.  E. coli (BL21) cells coding for appropriate enzyme variant were grown 
from glycerol stock overnight (37 °C, 250 rpm) in 5 ml TBamp. The pre-culture was used to inoculate 45 
mL of Hyperbroth medium (1 L Hyperbroth prepared from powder from AthenaES©, 0.1 mg mL-1 
ampicillin) in a 125 mL Erlenmeyer flask and this culture was incubated at 37 °C, 200 rpm for 
approximately 3 h. At OD600 = 1.8, the cultures were cooled to 22 °C and the shaking was reduced to 140 
rpm before inducing with IPTG (0.25 mM) and δ-aminolevulinic acid (0.50 mM). Cultures were 
harvested after 20 h and resuspended in nitrogen-free M9-N medium (1 L: 31 g Na2HPO4, 15 g KH2PO4, 
2.5 g NaCl, 0.24 g MgSO4, 0.010 g CaCl2) until the indicated OD600 (usually OD600 = 60) is obtained. 
Aliquots of the cell suspension were used for determination of the enzyme expression level (2–3 mL) 
after lysis.  
Anaerobic conditions: E. coli cells (OD600 = 60) were transferred to a crimped 6 mL vial and 
made anaerobic by degassing with argon for 5-10 min.  In parallel, glucose (50 μL, 250 mM) was added 
to 2 mL crimp vials that are sealed.  The headspaces of these vials were purged with argon for 5-10 min.  
If multiple reactions were being carried out in parallel, a maximum of 8 vials were connected via 
cannulae and degassed in series.  Cells (425 μL) were transferred to each vial via syringe and the olefin 
substrate was added (12.5 μL of a 800 mM solution of styrene in EtOH or a 400 mM solution of 
acrylamide 1 in EtOH), followed by EDA  (12.5 μL of a 350 mM or 400 mM solution in EtOH). The 
reactions were shaken on a table-top shake plate at room temperature for 5 h.  The reactions were 
quenched by addition of 25 μL of 3 M HCl, followed by 20 μL of the internal standard (20 mM 2-
phenylethanol solution in cyclohexane) and 1 mL cyclohexane. The mixture was transferred to a 2 mL 
Eppendorf tube, vortexed and then centrifuged (10,000x rcf, 30 s).  The organic layer was removed and 
analyzed by GC to determine yield and chiral SFC to determine enantioselectivity. 
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Aerobic conditions: Cell suspension was used without sparging with argon.  Cells (425 μL, OD600 
= 60) and glucose (50 μL, 250 mM) were combined in an unsealed 2 mL glass vial.  The olefin substrate 
was added (12.5 μL, 400 mM in EtOH), followed by EDA (12.5 μL, 400 mM in EtOH).  The vial was 
covered with foil then shaken at 35 rpm for 5 h.  The reactions were quenched by addition of 25 μL of 3 
M HCl, followed by 20 μL of the internal standard (20 mM 2-phenylethanol solution in cyclohexane) and 
1 mL cyclohexane. The mixture was transferred to a 2 mL Eppendorf tube, vortexed and then centrifuged 
(10,000x rcf, 30 s).  The organic layer was removed and analyzed by GC to determine yield and chiral 
SFC to determine enantioselectivity.
Analysis of crude reaction mixture: GC analysis of product was performed using J&W HP-5 
column (30 m x 0.32 mm, 0.25 µM film) with the method 90 °C hold 2 min, 90–110 at 6 °C/min, 110–
190 at 40 °C/min, 190–300 at 20 °C/min, 300 °C hold 1 min, 12.8 min total): internal standard (3.55 
min), retention times for the cis and trans products are listed in the characterization section below. 
Analytical SFC of product was performed on either Chiralpak AS column or OD column, eluting with 
iPrOH at 2.5 mL/min and detecting at 210 nm. Semi-preparative HPLC for all products was performed 
on 9.4 mm x 250 mm, 5 µm Agilent XDB-C18 column, detection at 210 nm, flow rate 3.0 mL/min, 
H2O/MeCN, gradient: 0 min 10% MeCN, 30 min 70% MeCN, hold 5 min, 40 min 95% MeCN
Calibration of Cyclopropanation Products 
Yields of cyclopropanation products were determined using calibration curves made with independently 
synthesized standards. Stock solutions of product were made at 120 or 160 mM  in DMSO.  To 4 samples 
containing cells at OD600 = 60, product was added from either of the stock solutions such that a final 
concentration of 1.5-6.0 or 2.0-8.0 mM product was obtained. Additional DMSO was added such that the 
total volume of organics added to each tube was 25 µL.  Next, 20 µL of a 20 mM stock solution of 
internal standard in cyclohexane was added to each Eppendorf tube, followed by 1 mL of cyclohexane.  
The Eppendorf tubes were vortexed and centrifuged (13,000 x rcm, 30 seconds). The organic layer was 
then analyzed by GC using J&W HP-5 column (30 m x 0.32 mm, 0.25 µM film: 90 °C hold 2 min, 90-
110 at 6 °C/min, 110-190 at 40 °C/min, 190–300 at 20 °C/min, 300 °C hold 1 min, 12.8 min total). The 
ratio of the areas under the internal standard and product peaks was plotted against the concentration for 
each solution (1.5 to 6.0 mM or 2.0 to 8.0 mM).
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Amino Acid Sequences
Table S1. List of mutations in enzyme variants, relative to wild type BM3 holoprotein (WT). All 
mutations listed below are for the heme domain. There are no mutations present in the reductase domain 
relative to wild type.
Enzyme Amino acid substitution with respect to WT
T268A-AxH T268A, C400H
BM3-HStar V78M, L181V, T268A, C400H, L437W
The amino acid sequence for WT (holoprotein) is as follows:
>SEQ ID NO:1: gi|142798|gb|AAA87602.1| cytochrome P-450:NADPH-P-450 reductase 
precursor [Bacillus megaterium]
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESRFDKNLSQALK
FVRDFAGDGLFTSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERLNADEHIEVPEDMTRLTLDTI
GLCGFNYRFNSFYRDQPHPFITSMVRALDEAMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVDKIIADRKASGEQS
DDLLTHMLNGKDPETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVKNPHVLQKAAEEAARVLVDPVPSYKQ
VKQLKYVGMVLNEALRLWPTAPAFSLYAKEDTVLGGEYPLEKGDELMVLIPQLHRDKTIWGDDVEEFRPERFENPSA
IPQHAFKPFGNGQRACIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETLTLKPEGFVVKAKSKKIPLGGIPSP
STEQSAKKVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLDSHAGNLPREGAVLIVTASYNG
HPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAAKGAENIADRGEADASDDFEGTYEE
WREHMWSDVAAYFNLDIENSEDNKSTLSLQFVDSAADMPLAKMHGAFSTNVVASKELQQPGSARSTRHLEIELPKEA
SYQEGDHLGVIPRNYEGIVNRVTARFGLDASQQIRLEAEEEKLAHLPLAKTVSVEELLQYVELQDPVTRTQLRAMAA
KTVCPPHKVELEALLEKQAYKEQVLAKRLTMLELLEKYPACEMKFSEFIALLPSIRPRYYSISSSPRVDEKQASITV
SVVSGEAWSGYGEYKGIASNYLAELQEGDTITCFISTPQSEFTLPKDPETPLIMVGPGTGVAPFRGFVQARKQLKEQ
GQSLGEAHLYFGCRSPHEDYLYQEELENAQSEGIITLHTAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICG
DGSQMAPAVEATLMKSYADVHQVSEADARLWLQQLEEKGRYAKDVWAGHHHHHH
The nucleotide sequence for WT (holoprotein) is as follows:
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAAACACAGATAAACC
GGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATTCGAGGCGCCTGGTCGTGTAACGCGCT
ACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGATGAATCACGCTTTGATAAAAACTTAAGTCAAGCGCTTAAA
TTTGTACGTGATTTTGCAGGAGACGGGTTATTTACAAGCTGGACGCATGAAAAAAATTGGAAAAAAGCGCATAATAT
CTTACTTCCAAGCTTCAGTCAGCAGGCAATGAAAGGCTATCATGCGATGATGGTCGATATCGCCGTGCAGCTTGTTC
AAAAGTGGGAGCGTCTAAATGCAGATGAGCATATTGAAGTACCGGAAGACATGACACGTTTAACGCTTGATACAATT
GGTCTTTGCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCCTCATCCATTTATTACAAGTATGGTCCG
TGCACTGGATGAAGCAATGAACAAGCTGCAGCGAGCAAATCCAGACGACCCAGCTTATGATGAAAACAAGCGCCAGT
TTCAAGAAGATATCAAGGTGATGAACGACCTAGTAGATAAAATTATTGCAGATCGCAAAGCAAGCGGTGAACAAAGC
GATGATTTATTAACGCATATGCTAAACGGAAAAGATCCAGAAACGGGTGAGCCGCTTGATGACGAGAACATTCGCTA
TCAAATTATTACATTCTTAATTGCGGGACACGAAACAACAAGTGGTCTTTTATCATTTGCGCTGTATTTCTTAGTGA
AAAATCCACATGTATTACAAAAAGCAGCAGAAGAAGCAGCACGAGTTCTAGTAGATCCTGTTCCAAGCTACAAACAA
GTCAAACAGCTTAAATATGTCGGCATGGTCTTAAACGAAGCGCTGCGCTTATGGCCAACTGCTCCTGCGTTTTCCCT
ATATGCAAAAGAAGATACGGTGCTTGGAGGAGAATATCCTTTAGAAAAAGGCGACGAACTAATGGTTCTGATTCCTC
AGCTTCACCGTGATAAAACAATTTGGGGAGACGATGTGGAAGAGTTCCGTCCAGAGCGTTTTGAAAATCCAAGTGCG
ATTCCGCAGCATGCGTTTAAACCGTTTGGAAACGGTCAGCGTGCGTGTATCGGTCAGCAGTTCGCTCTTCATGAAGC
AACGCTGGTACTTGGTATGATGCTAAAACACTTTGACTTTGAAGATCATACAAACTACGAGCTCGATATTAAAGAAA
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CTTTAACGTTAAAACCTGAAGGCTTTGTGGTAAAAGCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCT
AGCACTGAACAGTCTGCTAAAAAAGTACGCAAAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGG
TTCAAATATGGGAACAGCTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATGAGCAAAGGATTTGCACCGCAGG
TCGCAACGCTTGATTCACACGCCGGAAATCTTCCGCGCGAAGGAGCTGTATTAATTGTAACGGCGTCTTATAACGGT
CATCCGCCTGATAACGCAAAGCAATTTGTCGACTGGTTAGACCAAGCGTCTGCTGATGAAGTAAAAGGCGTTCGCTA
CTCCGTATTTGGATGCGGCGATAAAAACTGGGCTACTACGTATCAAAAAGTGCCTGCTTTTATCGATGAAACGCTTG
CCGCTAAAGGGGCAGAAAACATCGCTGACCGCGGTGAAGCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAA
TGGCGTGAACATATGTGGAGTGACGTAGCAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAATCTAC
TCTTTCACTTCAATTTGTCGACAGCGCCGCGGATATGCCGCTTGCGAAAATGCACGGTGCGTTTTCAACGAACGTCG
TAGCAAGCAAAGAACTTCAACAGCCAGGCAGTGCACGAAGCACGCGACATCTTGAAATTGAACTTCCAAAAGAAGCT
TCTTATCAAGAAGGAGATCATTTAGGTGTTATTCCTCGCAACTATGAAGGAATAGTAAACCGTGTAACAGCAAGGTT
CGGCCTAGATGCATCACAGCAAATCCGTCTGGAAGCAGAAGAAGAAAAATTAGCTCATTTGCCACTCGCTAAAACAG
TATCCGTAGAAGAGCTTCTGCAATACGTGGAGCTTCAAGATCCTGTTACGCGCACGCAGCTTCGCGCAATGGCTGCT
AAAACGGTCTGCCCGCCGCATAAAGTAGAGCTTGAAGCCTTGCTTGAAAAGCAAGCCTACAAAGAACAAGTGCTGGC
AAAACGTTTAACAATGCTTGAACTGCTTGAAAAATACCCGGCGTGTGAAATGAAATTCAGCGAATTTATCGCCCTTC
TGCCAAGCATACGCCCGCGCTATTACTCGATTTCTTCATCACCTCGTGTCGATGAAAAACAAGCAAGCATCACGGTC
AGCGTTGTCTCAGGAGAAGCGTGGAGCGGATATGGAGAATATAAAGGAATTGCGTCGAACTATCTTGCCGAGCTGCA
AGAAGGAGATACGATTACGTGCTTTATTTCCACACCGCAGTCAGAATTTACGCTGCCAAAAGACCCTGAAACGCCGC
TTATCATGGTCGGACCGGGAACAGGCGTCGCGCCGTTTAGAGGCTTTGTGCAGGCGCGCAAACAGCTAAAAGAACAA
GGACAGTCACTTGGAGAAGCACATTTATACTTCGGCTGCCGTTCACCTCATGAAGACTATCTGTATCAAGAAGAGCT
TGAAAACGCCCAAAGCGAAGGCATCATTACGCTTCATACCGCTTTTTCTCGCATGCCAAATCAGCCGAAAACATACG
TTCAGCACGTAATGGAACAAGACGGCAAGAAATTGATTGAACTTCTTGATCAAGGAGCGCACTTCTATATTTGCGGA
GACGGAAGCCAAATGGCACCTGCCGTTGAAGCAACGCTTATGAAAAGCTATGCTGACGTTCACCAAGTGAGTGAAGC
AGACGCTCGCTTATGGCTGCAGCAGCTAGAAGAAAAAGGCCGATACGCAAAAGACGTGTGGGCTGGGCTCGAGCACC
ACCACCACCACCACTGAGATCCGGCTGCTAACAAAGC
General Procedures for Synthesis of Acrylamides 5a–5g
To a solution of atropic acid (444 mg, 3.0 mmol) in DCM (6 mL, 0.5 M) at 0 ºC was added oxalyl 
chloride (0.31 mL, 3.6 mmol) dropwise, followed by catalytic amount of DMF. The resulting colorless 
solution was then warmed to room temperature and stirred for 2 h, upon which it turned slightly yellow. 
After cooling to 0 ºC, saturated NaHCO3 (6 mL) was added, followed by the appropriate amine (4.5 
mmol, 1.5 eq) dropwise. The resulting solution was stirred vigorously until a uniform emulsion  was 
obtained at room temperature overnight. The organic and aqueous layers were separated and the aqueous 
layer was extracted with Et2O (2 x 5 mL). The combined organic layer was washed with H2O (5 mL), and 
brine (5 mL), dried over Na2SO4, and concentrated in vacuo. When necessary, purification was 
performed with silica gel chromatography. Spectral data for 5a–5f are in agreement with those reported 
in the literature.2,3,4,5,6
5g
1H NMR (500 MHz, CDCl3): δ 7.46–7.38 (m, 2H), 7.34–7.23 (m, 4H), 7.09–6.98 (m, 3H), 5.70 (s, 1H), 
5.47 (s, 1H), 3.81 (s, 2H), 2.74–2.66 (m, 2H), 2.01–1.86 (m, 2H).
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13C NMR (CDCl3, 126 MHz): δ 170.0, 146.2, 138.5, 136.4, 128.6, 128.4, 126.2, 126.0, 125.0, 124.6, 
116.9, 45.8, 26.9, 24.0.
General Procedures for Synthesis of Acrylamides 7a–7f
To a solution of the appropriately-substituted phenylacetic acid (3.0 mmol) in DCM (6 mL) was added 
oxalyl chloride (0.31 mL, 3.6 mmol) dropwise, followed by catalytic amount of DMF. The resulting 
colorless solution was then stirred at room temperature for 2 h, upon which it turned slightly yellow. 
Saturated NaHCO3 (6 mL) was added, followed by Et2NH (4.5 mmol, 1.5 eq) dropwise. The resulting 
solution was stirred vigorously (uniform emulsion) at room temperature overnight. The organic and 
aqueous layers were separate and the aqueous layer was extracted with Et2O (2 x 5 mL). The combined 
organic layer was washed with H2O (5 mL), and brine (5 mL), dried over Na2SO4, and concentrated in 
vacuo. The resulting oil was used for the next step without further purification.
To a solution of the crude diethylacetamide (1 mmol) in DMF (4 mL) was added Cs2CO3 (977 mg, 3 
mmol, 3 eq), HCHO (60 mg, 2 mmol, 2 eq), and tetrabutylammonium bromide (81 mg, 0.25 mmol, 0.25 
eq). The resulting suspension was stirred vigorously and heated to 80 ºC for 24 h. After cooling to room 
temperature, the reaction was quenched with H2O (5 mL). The organic and aqueous layers were separated 
and the aqueous layer was extracted with Et2O (2 x 5 mL). The combined organic layer was washed with 
H2O (5 mL) and brine (5 mL), dried over Na2SO4, and concentrated in vacuo. After a short silica plug 
eluting  with 2:1 hexanes:EtOAc, a pale yellow oil was obtained which was pure enough to be used for 
the next step without purification. Spectral data for 7c and 7d are in agreement with those reported in the 
literature.7
7a (Yield = 86%)
1H NMR (500 MHz, CDCl3): δ 7.27–7.23 (m, 4H), 5.68 (s, 1H), 5.31 (s, 1H), 3.52 (q, J = 7.1 Hz, 2H), 
3.23 (q, J = 7.1 Hz, 2H), 2.36 (s, 3H), 1.23 (t, J = 7.1 Hz, 3H), 1.02 (t, J = 7.1 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 170.4, 145.9, 138.4, 135.9, 129.4, 128.7, 126.4, 122.9, 112.9, 42.9, 38.9, 
21.5, 14.1, 12.9.
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7b (Yield = 81%)
1H NMR (500 MHz, CDCl3): δ 7.32 (d, J = 8.2 Hz, 2H), 7.15 (d, J = 8.0, 2H), 5.65 (s, 1H), 5.26 (s, 1H), 
3.49 (dq, J = 7.7, 6.7 Hz, 2H), 3.22 (dq, J = 7.7, 6.7 Hz, 2H), 2.35 (s, 3H), 1.21 (td, J = 7.2, 0.9 Hz, 3H), 
1.00 (td, J = 7.1, 0.8 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 170.5, 145.7, 138.5, 133.2, 129.6, 125.7, 112.13, 42.9, 38.9, 21.3, 14.1, 
12.9.
7e (Yield = 91%)
1H NMR (500 MHz, CDCl3): δ 7.64–7.61 (m, 2H), 7.59–7.55 (m, 2H), 5.79 (s, 1H), 5.46 (s, 1H), 3.53 
(q, J = 7.1 Hz, 2H), 3.24 (q, J = 7.1 Hz, 2H), 1.24 (t, J = 7.1 Hz, 3H), 1.04 (t, J = 7.1 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 169.5, 144.6, 139.5, 130.4 (q, J = 32.2 Hz), 126.1, 125.9 (q, J = 3.8 Hz), 
124.1 (q, J = 272.8 Hz), 115.3, 43.0, 39.1, 14.2, 12.9.
7f (Yield = 85%)
1H NMR (500 MHz, CDCl3): δ 7.91–7.77 (m, 4H), 7.64 (dd, J = 8.5, 1.9 Hz, 1H), 7.55–7.44 (m, 2H), 
5.84 (s, 1H), 5.43 (s, 1H), 3.57 (q, J = 7.1 Hz, 2H), 3.26 (q, J = 7.1 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H), 1.02 
(t, J = 7.1 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 170.4, 145.7, 133.5, 133.4, 133.2, 128.6, 128.5, 127.7, 126.5, 125.3, 
123.2, 123.2, 113.5, 42.9, 39.0, 14.2, 12.94.
Synthesis of acrylate 9
To a solution of the corresponding ethyl ester (0.5 mmol) in DMF (3 mL) was added paraformaldehyde 
(1.0 mmol, 2 eq), followed by K2CO3 (0.5 mmol). The resulting suspension was stirred vigorously and 
heated to 70 ºC overnight. The organic and aqueous layers were separated and the aqueous layer was 
extracted with Et2O (2 x 5 mL). The combined organic layer was washed with H2O (5 mL), and brine (5 
mL), dried over Na2SO4, and concentrated in vacuo. After a short silica plug (washing with 2:1 
hexanes:EtOAc), a pale yellow oil was obtained which was pure enough to be used for the next step 
without further purification. Yield = 88%.
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Preparative Scale Whole Cell Aerobic Reactions
For characterization purposes, the aerobic reactions were scaled up as follows: Cells (8.5 mL, OD600 = 
60) and glucose (1.0 mL,  250 mM) were combined in an unsealed scintillation vial. The olefin substrate 
was added (0.25 mL, 400 mM in EtOH), followed by EDA (0.25 mM, 400 mM in EtOH). The vial was 
capped and then shaken at 35 rpm for 5 h. The reactions were quenched by addition of 0.25 mL of 3 M 
HCl, poured into a Falcon tube, extracted with 1:1 EtOAc:hexanes (7.5 mL), and centrifuged (5,000 rpm, 
5 min). The organics were collected, and this extraction sequence was repeated once. The organics were 
combined, dried with Na2SO4, and concentrated in vacuo. The crude product was purified via semi-
preparative HPLC, with the exception of 10, which was purified by silica gel chromatography (1;1 
Hexanes:DCM to 100% DCM).
Characterization Data for Cyclopropanes
6a
1H NMR (400 MHz, CDCl3): δ 7.36–7.20 (m, 5H), 4.19 (ddt, J = 7.2, 5.4, 2.6 Hz, 2H), 2.94 (s, 3H), 2.90 
(s, 3H), 2.43 (dd, J = 8.3, 6.3, 1H), 2.14 (dd, J = 6.4, 4.9 Hz, 1H), 1.51 (dd, J = 8.4, 5.1 Hz, 1H), 1.28 (td, 
J = 7.2, 1.8 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 170.9, 168.5, 138.8, 129.0, 127.4, 126.3, 61.1, 38.8, 37.3, 35.8, 28.9, 
21.8, 14.4.
HRMS (m/z): calcd for C15H19O3N, [M+H]+, 262.1443; found, 262.1446;
GC: Using method described on page SI-4, tR (min): cis = 9.25, trans = 9.42.
HPLC: Using method described on page SI-4, tR (min) = 21.7.
SFC: AS column, 4% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 6.45, minor = 7.53.
6b
1H NMR (500 MHz, CDCl3): δ 7.36–7.20 (m, 5H), 4.39–3.98 (m, 2H), 3.23 (s, 3H), 3.11 (s, 3H), 2.51 
(dd, J = 8.6, 6.3 Hz, 1H), 2.09 (t, J = 5.6 Hz, 1H), 1.58 (d, J = 4.4 Hz, 1H), 1.28 (dd, J = 7.8, 6.5 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 171.4, 138.8, 128.7, 127.8, 127.5, 110.2, 61.1, 60.8, 38.9, 33.6, 26.4, 
20.8, 14.3.
HRMS (m/z): calcd for C15H19O4N, [M+H]+, 278.1392; found, 278.1398;
GC: Using method described on page SI-4, tR (min): cis = 9.22, trans = 9.40.
HPLC: Using method described on page SI-4, tR = 23.9 min.
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SFC: OD column, 10% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 3.88, minor = 4.40.
6c
1H NMR (500 MHz, CDCl3): δ 7.36–7.20 (m, 5H), 4.19 (qd, J = 7.1, 1.9 Hz, 2H), 3.54 –3.43 (m, 2H), 
3.39–3.28 (m, 1H), 3.29–3.16 (m, 1H), 2.41 (dd, J = 8.4, 6.2 Hz, 1H), 2.18 (dd, J = 6.2, 4.9 Hz, 1H), 
1.86–1.68 (m, 4H), 1.49 (dd, J = 8.4, 4.9 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 171.0, 166.8, 138.6, 128.9, 127.4, 126.7, 61.1, 46.6, 46.4, 40.1, 28.3, 
26.2, 24.2, 21.2, 14.4.
HRMS (m/z): calcd for C17H21O3N, [M+H]+, 288.1600; found, 288.1591;
GC: Using method described on page SI-4, tR (min): cis = 10.51, trans = 10.60.
HPLC: Using method described on page SI-4, tR = 23.5 min.
SFC: AS column, 10% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 5.12, minor = 6.54.
6d
1H NMR (500 MHz, CDCl3): δ 7.36–7.20 (m, 5H), 4.26–4.11 (m, 2H), 3.83–3.66 (m, 1H), 3.51 (ddd, J = 
13.3, 6.7, 3.8 Hz, 1H), 3.45–3.32 (m, 1H), 3.25 (ddd, J = 13.3, 8.2, 3.6 Hz, 1H), 2.46 (dd, J = 8.4, 6.2 Hz, 
1H), 2.16 (dd, J = 6.2, 4.9 Hz, 1H), 1.59–1.45 (m, 4H) 1.50 (dd, J = 8.3, 5.0 Hz, 1H), 1.29 (t, J = 7.1 Hz, 
3H), 1.26–1.09 (m, 2H).
13C NMR (CDCl3, 126 MHz): δ 170.9, 166.9, 139.1, 128.9, 127.3, 126.4, 61.1, 46.7, 43.3, 38.8, 28.5, 
25.7, 25.5, 24.6, 21.7, 14.4.
HRMS (m/z): calcd for C18H23O3N, [M+H]+, 302.1756; found, 302.1770;
GC: Using method described on page SI-4, tR (min): cis = 10.68, trans = 10.81.
HPLC: Using method described on page SI-4, tR = 27.4 min.
SFC: AS column, 10% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 4.06, minor = 4.36.
6e
1H NMR (500 MHz, CDCl3): δ 7.36–7.20 (m, 5H), 4.45–4.05 (m, 2H), 3.71–3.65 (m, 1H), 3.64–3.55 (m, 
3H), 3.51–3.43 (m, 1H), 3.42–3.20 (m, 3H), 2.49 (dd, J = 8.4, 6.2 Hz, 1H), 2.16 (dd, J = 6.2, 4.9 Hz, 1H), 
1.50 (dd, J = 8.5, 4.9 Hz, 1H), 1.30 (t, J = 7.1 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 170.7, 167.4, 138.5, 129.1, 127.6, 126.2, 66.8, 66.3, 61.3, 46.3, 42.7, 
38.4, 28.3, 21.7, 14.4.
SI-13
HRMS (m/z): calcd for C17H21O4N, [M+H]+, 304.1549; found, 304.1538;
GC: Using method described on page SI-4, tR (min): cis = 10.60, trans = 10.77.
HPLC: Using method described on page SI-4, tR (min) = 21.0.
SFC: AS column, 5% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 5.98, minor = 6.47.
6f 
1H NMR (500 MHz, CDCl3): δ 7.40–7.18 (m, 6H), 7.14–7.09 (m, 2H), 6.94–6.82 (m, 2H), 4.23 (q, J = 
7.2 Hz, 2H), 3.27 (s, 3H), 1.97 (t, J = 7.3 Hz, 1H), 1.73 (t, J = 5.9 Hz, 1H), 1.37–1.25 (m, 4H).
13C NMR (CDCl3, 126 MHz): δ 171.5, 168.2, 143.7, 139.7, 129.1, 128.5, 127.9, 127.5, 127.2, 61.1, 
39.8, 38.7, 30.1, 21.2, 14.4.
HRMS (m/z): calcd for C20H21O3N, [M+H]+, 324.1600; found, 324.1596;
GC: Using method described on page SI-4, tR (min): cis = 10.94, trans = 11.11.
HPLC: Using method described on page SI-4, tR (min) = 30.8.
SFC: OD column, 10% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 6.27, minor = 7.09.
6g
1H NMR (500 MHz, C6D6, 25 ºC): δ 8.49 (brs, 1H), 7.59–6.70 (m, 8H), 4.14–3.89 (m, 2H), 3.20 (brs, 
1H), 2.70–1.83 (brm, 3H), 2.24 (dt, J = 15.8, 6.6 Hz, 1H), 1.41–1.06 (brm, 1H), 1.24 (dd, J = 8.2, 5.4 Hz, 
1H), 0.97 (t, J = 7.1 Hz, 3H).
1H NMR (500 MHz, C6D6, 65 ºC): δ 7.68 (brs, 1H), 7.36 (d, J = 7.7 Hz, 2H), 7.12–6.81 (m, 6H), 4.15–
3.92 (m, 3H), 3.29 (dt, J = 12.6, 5.8 Hz, 1H), 2.47 (dd, J = 15.2, 7.6 Hz, 1H), 2.31 (dt, J = 15.8, 6.6 Hz, 
1H), 2.12–2.21 (m, 1H), 1.95 (brs, 1H), 1.67 (brs, 1H), 1.37–1.31 (m, 1H), 1.29 (dd, J = 8.2, 5.4 Hz, 1H), 
1.04 (t, J = 7.1, 3H).
13C NMR (C6D6, 126 MHz): δ 170.8, 167.7, 146.9, 139.9, 129.0, 128.6, 127.3, 126.9, 126.0, 125.4, 
124.9, 61.0, 44.4, 39.7, 26.9, 23.8, 21.6, 14.3.
HRMS (m/z): calcd for C22H23O3N, [M+H]+, 350.1756; found, 350.1760;
GC: Using method described on page SI-4, tR (min): cis = 12.30, trans = 12.38.
HPLC: Using method described on page SI-4, tR (min) = 35.6.
SFC: OD column, 10% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 10.17, minor = 11.21.
SI-14
8a
1H NMR (500 MHz, CDCl3): δ 7.20 (t, J = 7.6 Hz, 1H), 7.14 (td, J = 1.6, 0.7 Hz, 1H), 7.07 (dddt, J = 
12.6, 7.5, 1.8, 1.0 Hz, 2H), 4.18 (qd, J = 7.2, 1.1 Hz, 2H), 3.59–3.41 (m, 2H), 3.19 (ddq, J = 38.7, 14.2, 
7.1 Hz, 2H), 2.43 (dd, J = 8.4, 6.2 Hz, 1H), 2.33 (s, 3H), 2.17 (dd, J = 6.2, 4.9 Hz, 1H), 1.48 (dd, J = 8.4, 
4.9 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H), 1.10 (t, J = 7.1 Hz, 3H), 0.78 (t, J = 7.1 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 170.8, 167.9, 139.1, 138.6, 128.8, 128.1, 127.3, 123.4, 61.1, 41.5, 39.4, 
39.1, 28.3, 21.5, 21.3, 14.4, 13.2, 12.4.
HRMS (m/z): calcd for C18H25O3N, [M+H]+, 304.1913; found, 304.1917;
GC: Using method described on page SI-4, tR (min): cis = 9.80, trans = 10.09.
HPLC: Using method described on page SI-4, tR (min) = 29.8.
SFC: AS column, 2% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 7.66, minor = 9.24.
8b
1H NMR (500 MHz, CDCl3): δ 7.23–7.17 (m, 2H), 7.15–7.08 (m, 2H), 4.18 (qd, J = 7.1, 1.6 Hz, 2H), 
3.60–3.36 (m, 2H), 3.30–3.09 (m, 2H), 2.41 (dd, J = 8.3, 6.2 Hz, 1H), 2.33 (s, 3H), 2.16 (dd, J = 6.2, 4.9 
Hz, 1H), 1.46 (dd, J = 8.4, 4.8 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H), 1.09 (t, J = 7.1 Hz, 3H), 0.78 (t, J = 7.1 
Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 170.9, 167.9, 137.0, 136.2, 129.6, 129.0, 128.8, 126.4, 61.0, 41.5, 39.4, 
38.9, 28.3, 21.2, 21.1, 14.4, 13.2, 12.5.
HRMS (m/z): calcd for C18H25O3N, [M+H]+, 340.1913; found, 340.1917;
GC: Using method described on page SI-4, tR (min): cis = 9.93, trans = 10.19.
HPLC: Using method described on page SI-4, tR (min) = 29.9.
SFC: AS column, 2% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 8.85, minor = 10.47.
8c
1H NMR (500 MHz, CDCl3): δ 7.25 (d, J = 8.9 Hz, 2H), 6.85 (d, J = 8.9, 2H), 4.17 (qd, J = 6.3, 5.5, 3.4 
Hz, 2H), 3.80 (s, 3H), 3.54 (dq, J = 15.0, 7.5 Hz, 1H), 3.45 (dq, J = 14.1, 7.1 Hz, 1H), 3.20 (ddt, J = 28.0, 
14.2, 7.1 Hz, 2H), 2.37 (dd, J = 8.2, 6.3 Hz, 1H), 2.14 (dd, J = 6.3, 4.7 Hz, 1H), 1.45 (dd, J = 8.2, 4.7 Hz, 
1H), 1.29 (t, J = 7.1 Hz, 3H), 1.09 (t, J = 7.1 Hz, 3H), 0.79 (t, J = 7.1 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 170.9, 168.0, 159.0, 131.3, 127.9, 114.3, 61.0, 55.5, 41.5, 39.4, 38.6, 
28.3, 21.0, 14.4, 13.3, 12.5.
SI-15
HRMS (m/z): calcd for C18H25O4N, [M+H]+, 320.1862; found, 320.1866;
GC: Using method described on page SI-4, tR (min): cis = 10.56, trans = 10.84.
HPLC: Using method described on page SI-4, tR (min) = 26.6.
SFC: AS column, 4% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 6.49, minor = 7.50.
8d
1H NMR (500 MHz, CDCl3): δ 7.35–7.21 (m, 4H), 4.18 (qd, J = 7.1, 1.6 Hz, 2H), 3.58–3.36 (m, 2H), 
3.21 (ddq, J = 37.3, 14.2, 7.1 Hz, 2H), 2.38 (dd, J = 8.4, 6.2 Hz, 1H), 2.18 (dd, J = 6.3, 5.0 Hz, 1H), 1.47 
(dd, J = 8.4, 5.0 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H), 1.09 (t, J = 7.1 Hz, 3H), 0.82 (t, J = 7.1 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 170.5, 167.4, 137.8, 133.3, 130.2, 129.1, 128.6, 128.0, 61.2, 41.5, 39.5, 
38.5, 28.5, 21.2, 14.4, 13.3, 12.4.
HRMS (m/z): calcd for C17H22O3ClN, [M+H]+, 324.1366; found, 324.1368;
GC: Using method described on page SI-4, tR (min): cis = 10.29, trans = 10.56.
HPLC: Using method described on page SI-4, tR (min) = 31.1.
SFC: AS column, 4% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 5.47, minor = 5.91.
8e
1H NMR (500 MHz, CDCl3): δ 7.62–7.56 (m, 2H), 7.47–7.36 (m, 2H), 4.20 (qd, J = 7.1, 1.1 Hz, 2H), 
3.60–3.42 (m, 2H), 3.22 (ddq, J = 43.6, 14.2, 7.1 Hz, 2H), 2.45 (dd, J = 8.4, 6.3 Hz, 1H), 2.24 (dd, J = 
6.3, 5.1 Hz, 1H), 1.54 (dd, J = 8.5, 5.1 Hz, 1H), 1.30 (t, J = 7.1 Hz, 3H), 1.11 (t, J = 7.1 Hz, 3H), 0.82 (t, 
J = 7.1 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 170.3, 167.1, 143.4, 129.8 (q, J = 32.7 Hz), 126.9, 125.9 (q, J = 3.7 Hz), 
124.1 (q, J = 271.9 Hz), 61.3, 41.5, 39.6, 38.7, 28.8, 21.4, 14.3, 13.3, 12.4.
HRMS (m/z): calcd for C18H22 F3O3N, [M+H]+, 358.1630; found, 358.1635;
GC: Using method described on page SI-4, tR (min): cis = 9.28, trans = 9.54.
HPLC: Using method described on page SI-4, tR (min) = 31.8.
SFC: AS column, 1% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 6.82, minor = 7.41.
8f
1H NMR (500 MHz, CDCl3): δ 7.85–7.78 (m, 3H), 7.74 (dt, J = 1.4, 0.7 Hz, 1H), 7.53–7.43 (m, 3H), 
4.22 (qd, J = 7.2, 1.0 Hz, 2H), 3.65–3.43 (m, 2H), 3.23 (ddq, J = 28.4, 14.1, 7.0 Hz, 2H), 2.57 (dd, J = 
SI-16
8.4, 6.2 Hz, 1H), 2.26 (dd, J = 6.2, 4.9 Hz, 1H), 1.60 (dd, J = 8.4, 4.9 Hz, 1H), 1.32 (t, J = 7.1 Hz, 3H), 
1.12 (t, J = 7.1 Hz, 3H), 0.74 (t, J = 7.1 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 170.8, 167.7, 136.6, 133.5, 132.7, 128.8, 127.9, 127.7, 126.6, 126.2, 
125.1, 124.8, 61.2, 41.5, 39.5, 39.3, 28.4, 21.3, 14.4, 13.3, 12.5.
HRMS (m/z): calcd for C21H25O3N, [M+H]+, 340.1913; found, 340.1917;
GC: Using method described on page SI-4, tR (min): cis = 11.63, trans = 12.05.
HPLC: Using method described on page SI-4, tR (min) = 32.0.
SFC: AS column, 7% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 6.02, minor = 6.80.
10
1H NMR (500 MHz, CDCl3): δ 7.33 (d, J = 8.1 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 4.19 (qd, J = 7.1, 2.8 
Hz, 2H), 4.15–4.02 (m, 2H), 2.33 (s, 3H), 2.20 (dd, J = 8.5, 6.3 Hz, 1H), 2.08 (dd, J = 6.3, 4.9 Hz, 1H), 
1.48 (dd, J = 8.5, 4.9 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H).
13C NMR (CDCl3, 126 MHz): δ 170.9, 169.9, 137.8, 135.6, 130.6, 129.9, 129.4, 129.2, 61.5, 61.1, 38.9, 
28.1, 21.2, 19.0, 14.39, 14.2.
Rf = 0.23 (silica gel, DCM)
HRMS (m/z): calcd for C16H20O4, [M+H]+, 277.1440; found, 277.1442;
GC: Using method described on page SI-4, tR (min): cis = 8.77, trans = 9.00.
SFC: AS column, 1% IPA, 2.5 mL/min: λ = 210 nm, tR (min): major = 5.79, minor = 7.63.
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